Adamas Pharmaceuticals Inc. (ADMS) Trading Down 4.4%

adamas-pharmaceuticals-inc-adms-trading-down-44.jpg

Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) traded down 4.4% on Wednesday . The company traded as low as $17.25 and last traded at $17.29, with a volume of 432,397 shares traded. The stock had previously closed at $18.09.
A number of analysts have weighed in on the company. Mizuho increased their target price on Adamas Pharmaceuticals from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, September 8th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 2nd. Credit Suisse Group AG reiterated a “buy” rating and issued a $21.00 target price on shares of Adamas Pharmaceuticals in a research note on Monday, July 25th. Noble Financial reiterated a “buy” rating and issued a $25.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, July 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $38.00 target price on shares of Adamas Pharmaceuticals in a research note on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $32.11.
The firm’s 50 day moving average price is $14.65 and its 200 day moving average price is $15.51. The company’s market cap is $390.56 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/adamas-pharmaceuticals-inc-adms-trading-down-4-4.html

In other Adamas Pharmaceuticals news, Director William W. Ericson purchased 7,200 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The shares were acquired at an average price of $15.00 per share, with a total value of $108,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ix Lp Mdv purchased 50,919 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was acquired at an average cost of $14.79 per share, for a total transaction of $753,092.01. The disclosure for this purchase can be found here. Company insiders own 31.79% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Bow Street LLC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $7,369,000. Schwab Charles Investment Management Inc. raised its position in shares of Adamas Pharmaceuticals by 34.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 27,472 shares of the specialty pharmaceutical company’s stock valued at $416,000 after buying an additional 7,000 shares during the period. Metropolitan Life Insurance Co. NY acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $158,000. Point72 Asset Management L.P. acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $2,176,000. Finally, Highbridge Capital Management LLC acquired a new position in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $205,000. 74.65% of the stock is currently owned by institutional investors and hedge funds.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Adamas Pharmaceuticals Inc. (ADMS) Trading Down 4.4%"

Leave a comment

Your email address will not be published.


*